Q-Med AB: Invitation to conference call regarding interim report January-September, 2009

Q-Med AB: Invitation to conference call regarding interim report
January-September, 2009

Time: Friday, October 23, 2009 at 10.30 a.m. CET.

To join the conference: 	
Swedish dial in number: +46 8 5052 0114
UK dial in number: +44 207 1620 177

Q-Med participants: 	
Bengt Ågerup, CEO
Alexander Kotsinas, CFO
Karin Falck, Director Corporate Communications

Q-Med AB's Q3 report will be released 08.00 on October 23, 2009.

The slide presentation will be available at www.q-med.com, and
Investors/Presentations.

A recorded version of the presentation will be available for seven working days
on 
tel: Sweden +46 8 505 203 33 or UK +44 20 7031 4064, access code: 84 83 70.
	
Financial information from Q-Med during 2010
12  February Year-end Report 2009 
23  April Interim Report January - March 2010
28  April Annual General Meeting
22  July Interim Report January - June 2010
22  October Interim Report January - September 2010

Queries should be addressed to:
Karin Falck, Director Corporate Communications
Tel: +46 70 974 90 15

Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA™, for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane™ for body contouring, Durolane™ for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR, 
(a malformation of the urinary bladder) in children, and Solesta™ for the
treatment of fecal incontinence. Sales are made through the company's own
subsidiaries or distributors in over 70 countries. Q Med today has about 650
coworkers, with approximately 400 at the company's head office and production
facility in Uppsala, Sweden. 
Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic. 


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.